12:00 AM
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tradjenta: Phase III data

A pair of double-blind, Asian Phase III trials in Type II diabetics showed that once-daily 5 mg oral linagliptin with and without metformin, respectively, each met the primary endpoint of reducing mean HbA1c from baseline to week 24 vs. placebo. In the monotherapy trial in 300 patients with inadequately controlled Type II diabetes, linagliptin...

Read the full 249 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >